Research from the UNC School of Medicine lab of Jenny Ting, PhD, shows that the widely used drug metformin reduces metabolism of infected T cells to suppress HIV replication.
Researchers have discovered a novel and druggable insulin inhibitory receptor, named inceptor. The latest study from Helmholtz Zentrum München, the Technical University of Munich and the German Center for Diabetes Research is a significant milestone for diabetes research as the scientific community celebrates 100 years of insulin and 50 years of insulin receptor discovery. The blocking of inceptor function leads to an increased sensitisation of the insulin signaling pathway in pancreatic beta cells. This might allow protection and regeneration of beta cells for diabetes remission.
People on a low-fat, plant-based diet ate fewer daily calories but had higher insulin and blood glucose levels, compared to when they ate a low-carbohydrate, animal-based diet, according to a small but highly controlled study at the National Institutes of Health.
All prediabetes is not the same: in people in the preliminary stages of type 2 diabetes, there are six clearly distinguishable subtypes, which differ in the development of the disease, diabetes risk, and the development of secondary diseases. This is shown in a study by the Institute for Diabetes Research and Metabolic Diseases (IDM) of Helmholtz Zentrum München at the University of Tübingen, Tübingen University Hospital and the German Center for Diabetes Research (DZD). The results have now been published in Nature Medicine. The new classification can help in the future to prevent the manifestation of diabetes or the development of diabetes complications through targeted prevention.
Losing a few kilograms in weight almost halves people’s risk of developing Type 2 diabetes – according to a large scale research study led by the Norfolk and Norwich University Hospital and the University of East Anglia.
A study presented at UEG Week 2020 suggests a minimally-invasive, outpatient procedure combined with GLP-1 RA therapy could help diabetics eliminate the need for insulin therapy.
Metformin is the first-line drug that can lower blood sugar levels in type 2 diabetes patients. One third of patients do not respond to metformin treatment and 5 per cent experience serious side effects, which is the reason many choose to stop medicating. Researchers at Lund University in Sweden have now identified biomarkers that can show in advance how the patient will respond to metformin treatment via a simple blood test.